I’m all in with Pluristem!!!
Once approved for broader use, specifically treating COVID-19 patients. Pluristem has a significant advantage; supply, manufacturing, scalability, logistics infrastructure (rapid distribution), funding, a proven safety profile, and ethical sourcing of cells.
According to an article posted on bio space.com,
“PLX cells are derived from the placentas of young, healthy donors who have C-sections (after informed consent). Placentas provide an ethical source of cells, and they are readily available and in virtually unlimited supply. ‘One placenta can produce 20,000 doses.’
That ready supply, coupled with a well-developed, highly scalable manufacturing capability and logistics infrastructure are competitive advantages.
‘We have a lot of capacity in Israel and already have large quantities of cells distributed in the U.S. and Europe,’ she (Racheli Ofir, Ph.D., VP, research & intellectual property, Pluristem) said. That’s another advantage, enabling rapid distribution once the cells are approved for broader use. Shelf life is four years and counting.”
Source:
https://www.biospace.com/article/pluristem-advances-placental-cells-to-modulate-covid-19-cytokine-storm-/
Pluristem is leader, innovator, and it’s products are a trailblazer in biotechnology. I’m anticipating BIG things to come for PSTI in the coming days!!!